Small Cell Lung Cancer

The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.

Latest News

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com
Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

July 30th 2025

A retrospective analysis found whole brain radiation therapy alongside immune checkpoint inhibitors led to “brilliant” 2-year overall survival rates.

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com
Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

July 29th 2025

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com
Midkine May Play Key Role in SCLC

July 24th 2025

Emerging therapies, including immune checkpoint inhibitors and antibody-drug conjugates, could significantly impact SCLC treatment, authors of a recent review concluded. | Image credit: Vitalii Vodolazskyi - stock.adobe.com
Is a New Era of SCLC, LCNEC Treatments on the Horizon?

July 23rd 2025

The investigators found that patients with SCLC and cachexia were more likely to have problems with treatment. | Image credit: appledesign - stock.adobe.com
Cachexia Worsens Prognosis in Older Patients With Advanced SCLC

July 9th 2025

Multidisciplinary Approaches to Paraneoplastic LEMS

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.
Continuing Medical Education
View All
August 26th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 26th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Non-Small Cell Lung Cancer Outcomes With Pembrolizumab Plus Radiation
October 23rd 2020

Pembrolizumab Plus Radiation Therapy Improves NSCLC Outcomes, Study Finds

Rose McNulty
Researchers analyzed 2 randomized studies to learn how adding radiation therapy to pembrolizumab immunotherapy affects non-small cell lung cancer patient outcomes.
Woman Consulting With a Doctor
October 22nd 2020

Cancer Care Delays in COVID-19 Could Lead to Higher Morbidity, Mortality

Rose McNulty
Cancer screenings and treatments saw a sharp decline during the early months of the pandemic. The authors of a new study on the delays in care warn that the fallout may be grim.
Propelled by Targeted Therapies, NSCLC Mortality Fell Between 2013 to 2016
October 17th 2020

Propelled by Targeted Therapies, NSCLC Mortality Fell Between 2013 to 2016

Allison Inserro
Nearly 10,000 deaths from non–small-cell lung cancer (NSCLC) were likely delayed between 2014 to 2016, the researchers calculated.
Nivolumab Meets Primary Endpoint in Resectable NSCLC
October 16th 2020

Nivolumab Meets Primary Endpoint in Resectable NSCLC

AJMC Staff
The safety profile of nivolumab plus chemotherapy was also consistent with previously reported studies in NSCLC, the researchers said.
Phase 2 Trial for Sotorasib Yields Positive Results With Certain Type of NSCLC
October 10th 2020

Phase 2 Trial for Sotorasib Yields Positive Results With Certain Type of NSCLC

Skylar Jeremias
In announcing the topline results, Amgen said that sotorasib met the primary end point of centrally assessed objective response rate.
Dr Blythe Adamson: PD-L1 as a Predictive Biomarker in Lung Cancer Continues to Evolve
October 6th 2020

Dr Blythe Adamson: PD-L1 as a Predictive Biomarker in Lung Cancer Continues to Evolve

Personalized recommendations for patients with non–small cell lung cancer with squamous histology could benefit from research on treatment choice and biomarkers, noted Blythe Adamson, PhD, MPH, principal quantitative scientist at Flatiron Health.
Atezolizumab Leads to Longer OS for Some Types of Advanced NSCLC, Study Says
September 30th 2020

Atezolizumab Leads to Longer OS for Some Types of Advanced NSCLC, Study Says

Allison Inserro
Efficacy and safety of atezolizumab as first-line therapy for metastatic non–small cell lung cancer (NSCLC) with high levels of PD-L1 expression is not known, the authors said.
Combo Treatment Bests Cemiplimab Monotherapy, Phase 2 Data Show
September 30th 2020

Combo Treatment Bests Cemiplimab Monotherapy, Phase 2 Data Show

Maggie L. Shaw
Study results presented during the virtual European Society for Medical Oncology meeting demonstrated the superiority of cemiplimab (Libtayo) plus ipilimumab vs cemiplimab monotherapy for non–small cell lung cancer.
Phase 3 Trial Results Highlight Cemiplimab’s Potential in NSCLC
September 23rd 2020

Phase 3 Trial Results Highlight Cemiplimab’s Potential in NSCLC

Maggie L. Shaw
Data from the EMPOWER-Lung 1 trial of cemiplimab (Libtayo) monotherapy vs chemotherapy show why the fully-human monoclonal antibody could become a new treatment option for non–small cell lung cancer (NSCLC).
Sotorasib Shows Benefit for Patients With Certain Type of NSCLC
September 21st 2020

Sotorasib Shows Benefit for Patients With Certain Type of NSCLC

Allison Inserro
The KRAS mutation occurs in 13% of non–small cell lung cancers (NSCLC) and leads to worse outcomes in NSCLC.
Dr Melissa Johnson: COVID-19 Has Brought About Lasting Change to Medicine
September 18th 2020

Dr Melissa Johnson: COVID-19 Has Brought About Lasting Change to Medicine

Melissa L. Johnson, MD, associate director for lung cancer research at Sarah Cannon Research Institute and partner in Tennessee Oncology, speaks on changes necessitated by the coronavirus disease 2019 (COVID-19) pandemic and connecting virtually.
Image of lung cancer
September 17th 2020

Pandemic Altered Treatment Plans for Patients With Lung Cancer, Study Finds

Allison Inserro
More than half of the patients in this study, with either non–small or small cell lung cancer, experienced changes in their treatment plan during the coronavirus disease 2019 pandemic this spring.
Dr Melissa Johnson: Tiragolumab/Atezolizumab Potential New Treatment Option for NSCLC
September 9th 2020

Dr Melissa Johnson: Tiragolumab/Atezolizumab Potential New Treatment Option for NSCLC

Melissa L. Johnson, MD, associate director for lung cancer research at Sarah Cannon Research Institute and partner in Tennessee Oncology, discusses the potential of tiragolumab/atezolizumab for metastatic non–small cell lung cancer (NSCLC).
Dr Melissa Johnson: Treatment Advances Highlight the Immune System’s Importance in Lung Cancer
September 1st 2020

Dr Melissa Johnson: Treatment Advances Highlight the Immune System’s Importance in Lung Cancer

Melissa L. Johnson, MD, associate director for lung cancer research at Sarah Cannon Research Institute and partner in Tennessee Oncology, discussed the biggest gains in the lung cancer space that have contributed to improved survival for patients.
<1
...
678910

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo